United Kingdom approved first oral antiviral against Covid-19
Lagevrio will act as an inhibitor in virus replication and will be developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme laboratories
The UK Medicines and Health Products Regulatory Agency (MRHA) authorized the use of Lagevrio (Molnupiravir), an oral antiviral developed by the US laboratory Merck, which could become a crucial tool in the fight against Covid-19.
The MRHA, a scientific, autonomous and independent advisory body of the government, highlighted that the “rigorous and meticulous investigation process of safety, quality and effectiveness” determined that the “antiviral is safe and effective”. It is considered by the Commission of Human Medicines as the first antiviral medicine to be used in the treatment of Covid-19.
The regulatory agency explained that Lagevrio’s process of action consists of interfering in the replication of the virus, preventing it from duplicating, controlling it the body and minimizing the danger of the disease.
According to clinical tests, Lagevrio is more effective when ingested in the early stages of the disease, which is why it is recommended to apply it immediately after obtaining confirmation of the virus in the body or five days after presenting symptoms.
The United Kingdom has become the first country in the world to approve the use of an oral medicine to confront this terrible virus that has claimed the lives of many citizens globally. UK Health and Social Care Secretary Sajid Javid called it a “historic day” for the country.
He also highlighted the importance of having a drug that can be “taken at home”, which – in his opinion – will change “the game for the most vulnerable and immunosuppressed, who will soon be able to receive innovative treatment.”
M. Rodríguez
Source: finazasdigital
